Moderately dysplastic nevi re-excision not necessary

Moderately dysplastic nevi re-excision not necessary
Re-excision of mildly or moderately histologically dysplastic nevi that approach a microscopic border may not be necessary, as favorable long-term outcomes are achieved without re-excision, according to a study published online Nov. 5 in the Journal of the American Academy of Dermatology.

(HealthDay)—Re-excision of mildly or moderately histologically dysplastic nevi (HDN) that approach a microscopic border may not be necessary, as favorable long-term outcomes are achieved without re-excision, according to a study published online Nov. 5 in the Journal of the American Academy of Dermatology.

Thomas Hocker, M.D., of the in Rochester, Minn., and colleagues conducted a involving 115 patients who had an HDN that extended to within 0.2 mm of a microscopic punch, shave, or excision border and was not re-excised. The rate of melanoma development was assessed over time.

Of the 115 dysplastic , 66 were mildly dysplastic, 42 were moderately dysplastic, and seven were severely dysplastic. During an average follow-up of 17.4 years, the researchers found that no patient developed metastatic melanoma or melanoma at the site of removal of an HDN, including in the 63.4 percent of patients followed for more than 20 years.

"The long-term outcomes in our cohort provide evidence that routine re-excision of HDNs with mild or moderate dysplasia may not be necessary, if the entire clinically visible lesion is removed, even if the nevus approaches a histologic margin," the authors write. "Avoiding re-excision of these nevi encountered in daily practice would result in fewer surgical procedures, with associated decreases in morbidity, including cosmetic disfigurement, and health care utilization and costs."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Negative pigment network able to distinguish melanoma

date Oct 25, 2012

(HealthDay)—Negative pigment network (NPN) can be used to distinguish melanoma from Spitz nevus and other benign lesions, according to a study published online Oct. 11 in the Journal of the American Ac ...

Recommended for you

'Ebola will return', veteran scientist warns

date 8 hours ago

Congolese expert Jean-Jacques Muyembe may be little known to the public, but he has been one of the world's top Ebola investigators since the first epidemic erupted in central Africa in 1976.

Score IDs patients with upper extremity DVT at low risk

date 23 hours ago

(HealthDay)—For patients with upper-extremity deep vein thrombosis (DVT), six easily available factors can be used to create a score that identifies those at low risk of adverse events during the first ...

Combined drug treatment combats kidney disease

date May 29, 2015

A recent discovery by drug researchers whereby coupling specific cell membrane receptors has altered kidney cell function has triggered a re-think of how to treat chronic kidney disease (CKD) more effectively.

Active substance targeting dreaded hospital germs

date May 29, 2015

In the German Center for Infection Research (DZIF), scientists have conducted clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: a highly effective protein from bacteriophages ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.